Search
Now showing items 1-1 of 1
Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation.
(AMER SOC CLINICAL INVESTIGATION INC, 2024-01-16)
BACKGROUNDPhase 1 study of ATRinhibition alone or with radiation therapy (PATRIOT) was a first-in-human phase I study of the oral ATR (ataxia telangiectasia and Rad3-related) inhibitor ceralasertib (AZD6738) in advanced ...